# GBS Venture Partners

GBS Venture Partners is a Venture Capital based in Melbourne, Australia.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Melbourne, Australia
- **Region:** Oceania
- **Address:** Melbourne, Australia
- **Founded:** 1996
- **Assets under management:** Undisclosed
- **Website:** www.gbsventures.com.au
- **LinkedIn:** https://www.linkedin.com/company/gbs-venture-partners

## Regulatory record

- **Reports private funds:** No

## About

GBS Venture Partners is a life science venture capital group formed in 2002 following a management buyout of Rothschild Bioscience Managers Limited. The firm has made 93 investments, including a Series D investment in Moximed on August 13, 2024. GBS Venture Partners has 14 portfolio exits, with Ivantis exiting on November 08, 2021.

## Sectors

- Life Sciences
- Biotech
- Medical Devices
- Digital Health
- Pharmaceuticals

## Questions

### What stages does GBS Venture Partners target?

GBS invests from seed through expansion stage, primarily in life-science companies. The firm often anchors seed and Series A rounds in Australian and New Zealand-based biotech, medtech, and diagnostics companies, with reserves for follow-on through later clinical milestones.

### Which sectors does GBS explicitly avoid?

The firm does not invest outside human life sciences. It avoids consumer tech, enterprise software, fintech, and industrial technology. Its mandate is exclusively biomedical — therapeutics, devices, diagnostics, and related digital health tools with a clinical application pathway.

### How does GBS source proprietary deal flow?

GBS leans on decades-long relationships with Australian medical research institutes and universities, including the Walter and Eliza Hall Institute, Monash University, and the University of Queensland. These relationships surface science before it reaches a broader investor audience, forming a repeatable sourcing advantage.

### Who runs investment decisions at GBS?

Publicly available details on current investment committee leadership are limited. The firm has historically drawn its senior investment team from scientific, clinical, and operating backgrounds rather than pure finance, reflecting the technical nature of its underwriting. The exact current principals are not disclosed in the firm's public footprint.

## Related profiles

- [GBM Ventures](https://altss.com/profile/gbm-ventures)
- [GBV Capital](https://altss.com/profile/gbv-capital)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/gbs-venture-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology